Table 4.
siRNA employment in liver fibrosis.
| Target mRNA | Delivery System | Liver Fibrosis Model | Ref. |
|---|---|---|---|
| TGF-β1 * | Liposome | CCl4-induced murine model of liver fibrosis | Kim et al. [66] |
| TGF-β1 * | Lipofectamine | HSC-T6 | Cheng et al. [67] |
| PDGFR * | siRNA expression from glial fibrillary acidic protein promoter | CCl4-induced murine model of liver fibrosis and bile duct ligation induced chronic rat liver injury | Chen et al. [68] |
| PDGF α receptor * | Commercial liposome | LX2 | Lim et al. [69] |
| Type I collagen | Liposome | LX2; CCl4-induced murine model of liver fibrosis; spontaneous model of mouse biliary fibrosis | Calvente et al. [70] |
| Type I collagen | Lipid bound to vitamin A | LI-90; CCl4-induced murine model of liver fibrosis | Toriyabe et al. [71] |
| MMP2 * | Lipid bound to vitamin A | HSC-T6 | Li et al. [72] |
| TIMPs * | Electroporation | HSC isolated from normal livers of Sprague–Dawley rats. | Fowel et al. [73] |
| STAT3 * | Exosomes | HSC isolated from healthy mouse; CCl4-induced murine model of liver fibrosis | Tang et al. [74] |
* TGF-β1: Transforming growth factor TGF-β1; PDGFR: platelet-derived growth factor receptor; MMP2: matrix metalloproteinase 2; TIMPs: Tissue inhibitors of metalloproteinases; STAT3: signal transducer and activator of transcription 3.